Nasdaq
$41.54▲ 0.10%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.90BShares out 69.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 3d agoAfter-hours26.10.22 06:534Ownership#●●●
Enliven Therapeutics, Inc.
Insider Benjamin Hohl of Enliven Therapeutics filed a statement of changes in beneficial ownership of securities on October 19, 2026. This filing officially reports the insider's change in share holdings to the SEC.…more
$41.54+0.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 06:514Ownership
Enliven Therapeutics, Inc.
Enliven Therapeutics insider Helen Louise Collins filed a Form 4 report regarding changes in beneficial ownership of securities as of October 19, 2026. This filing serves as a standard disclosure of the insider's updated equity holdings.…more
$41.54+0.10%vs prev closeView filingShare - 5d agoAfter-hours26.10.20 05:16144Ownership
Enliven Therapeutics, Inc.
Enliven Therapeutics insider Helen Louise Collins has filed a Form 144 to propose the sale of company shares. This is a standard regulatory filing regarding an insider's plan to dispose of equity holdings.…more
$41.54+0.10%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6After-hours26.10.07 05:09#●●●#●●●#●●●
Enliven Therapeutics Reaches FDA Alignment on Phase 3 Trial Design
Enliven Therapeutics has reached an agreement with the FDA on the design for its Phase 3 trial of relcobatinib for chronic myeloid leukemia. The company expects to initiate the clinical trial before the end of the year.…more
$41.54+0.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.1Overnight26.09.01 16:57
●●●●●●●● ●●●●● ●●●●●●
Enliven Therapeutics will present Phase 1 clinical trial data for its blood cancer drug ELVN-001 at the SOHO Annual Meeting in September. This presentation serves as an encore of data previously shared at the 2026 EHA Congress.…more
$41.54+0.10%vs prev closeShareBenzinga
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report